2 citations
,
December 2013 in “Cancer research” In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.
6 citations
,
January 2010 in “Neoplasma” In this study, researchers found that shorter CA repeats in the ERbeta gene are correlated with PSA expression, and PSA immunoexpression is associated with increased disease-free survival in breast cancer.
21 citations
,
April 2016 in “International Journal of Oncology” This study found that treatment with the GnRH agonist Triptorelin significantly decreased invasion and expression of S100A4 and CYR61 in certain breast cancer cells, suggesting a potential role in slowing cancer progression.
59 citations
,
April 2016 in “Breast Cancer Research and Treatment” This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.
5 citations
,
June 2022 in “Frontiers in Endocrinology” This review discusses the role of the androgen receptor in breast cancer as a prognostic indicator and potential therapeutic target, highlighting its controversial therapeutic value and the need for further study.